dibromodulcitol + doxorubicin + fluoxymesterone + tamoxifen + vincristine

This is a multi-agent combination chemotherapy regimen composed of five drugs: - **Dibromodulcitol** (DBD): An alkylating agent that induces DNA single-strand breaks, leading to cytotoxicity in tumor cells[1][2][3]. - **Doxorubicin** (also known as Adriamycin): An anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, resulting in inhibition of DNA replication and repair. - **Fluoxymesterone**: A synthetic androgen used for its antineoplastic effects, particularly in hormone-responsive cancers. - **Tamoxifen**: A selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in breast tissue. - **Vincristine**: A vinca alkaloid that inhibits microtubule formation during mitosis. This combination brings together agents with different mechanisms—alkylation, topoisomerase inhibition, hormonal modulation, and microtubule disruption—to maximize antitumor efficacy. Such regimens are typically used for advanced or refractory cancers where multi-modal attack on cancer cell survival pathways is desired. While combinations including dibromodulcitol with other agents like doxorubicin and vincristine have been studied for breast cancer and other malignancies[5][6], the specific five-drug combination listed here does not correspond to a widely recognized named regimen but represents an experimental or investigational approach.